Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study | Zendy

Corey C. Ford | Zendy; Jeffrey A. Cohen | Zendy; Andrew Goodman | Zendy; John Lindsey | Zendy; Robert P. Lisak | Zendy; Christopher Luzzio | Zendy; Amy A. Pruitt | Zendy; John Rose | Zendy; Horea Rus | Zendy; Jerry S. Wolinsky | Zendy; Shaul Kadosh | Zendy; Emily Bernstein-Hanlon | Zendy; Yafit Stark | Zendy; Jessica K. Alexander | Zendy

Open Access

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study

Author(s) -

Corey C. Ford,

Jeffrey A. Cohen,

Andrew Goodman,

John Lindsey,

Robert P. Lisak,

Christopher Luzzio,

Amy A. Pruitt,

John Rose,

Horea Rus,

Jerry S. Wolinsky,

Shaul Kadosh,

Emily Bernstein-Hanlon,

Yafit Stark,

Jessica K. Alexander

Publication year - 2022

Publication title -

multiple sclerosis journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.729

H-Index - 131

eISSN - 1477-0970

pISSN - 1352-4585

DOI - 10.1177/13524585221094239

Subject(s) - glatiramer acetate , medicine , expanded disability status scale , multiple sclerosis , randomized controlled trial , placebo , clinical trial , pediatrics , immunology , alternative medicine , pathology

Glatiramer acetate (GA) is US-approved for relapsing multiple sclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore